Technology group Halma (LON:HLMA) reported H1 revenue and profit which hit a new record driven by growth across all three businesses. CEO Marc Ronchetti said the results meant the firm was ‘well placed’ to deliver on its FY27 guidance.
Record revenue and profit
For the six months to September, Halma reported revenue of £1.43 billion, up 15.8% on the previous year. Organic growth was 13.1%, with underlying growth in photonics revenue of around 30% in line with the firm’s expectations.
Adjusted EBIT (earnings before interest and taxes) increased by 22.5% to £354.4 million. Both EBIT and revenue were ahead of the company-compiled consensus, as was adjusted pre-tax profit which rose 21.1% to £327.7 million.
The company spent a record £516 million on acquisitions during H1, buying six companies. From the end of September it made a further two acquisitions for around £55 million and has a ‘healthy pipeline of opportunities’.
Halma H1 results and consensus estimates (all £ millions)
| H1 2027 | Change | H1 2027 Est | FY27 Est | |
| Revenue | 1,433 | +15.8% | 1,426 | 2,977 |
| Adjusted EBIT | 345.4 | +22.5% | 332.3 | 705 |
| Adj pre-tax profit | 327.7 | +21.1% | 310.8 | 668 |
Source: Company-compiled consensus and accounts
FY27 outlook confirmed
The firm said it had made a good start to H2 despite geopolitical uncertainty and ‘varied conditions’ in its companies’ end markets. For the year as a whole it expects to deliver low-double-digit organic revenue growth.
This guidance includes ‘premium’ growth of around 5% from the photonics business, implying a continued underlying growth rate of 30% for the business. Meanwhile, adjusted EBIT margins are expected to be in the range of 23.5% to 24%, slightly down on H1’s 24.1% margin.
The group says the guidance is supported by its order intake, which remains ahead of revenue both year-to-date and compared to a year ago.

We’ve always said Halma is a quality compounder, and today’s results demonstrate that perfectly. The combination of strong end markets and high organic growth together with well-chosen acquisitions has rewarded investors amply over time.
However, as with Diploma (LON:DPLM), another quality compounder, we fear the valuation is well up with events. To push on, the firm needs to raise its guidance, which it may yet do as we move through H2.
If H2 growth is similar to H1, though, that would put FY revenue at just under £3 billion, in line with the consensus. The question is, given the rating and investor expectations, is being in line good enough?
Also, organic growth is being driven by photonics, which by the firm’s own admission is experiencing ‘premium’ levels of demand. That will eventually tail off, meaning sales and earnings growth will slow to their normal rate. What happens then?




